KRYS Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 49.9%. Krystal Biotech, Inc.'s return on equity of 19.91% beat CorMedix, Inc.'s return on equity of 95.25%.

Krystal Biotech, Inc. has a consensus price target of $288.70, signalling upside risk potential of 3.39%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 91.46%. Given that CorMedix, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe CorMedix, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Krystal Biotech, Inc.'s net income of $79.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 41.88x while CorMedix, Inc.'s PE ratio is 3.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 22.32x versus 2.61x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

DexCom, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 23.47%. Krystal Biotech, Inc.'s return on equity of 19.91% beat DexCom, Inc.'s return on equity of 30.94%.

Krystal Biotech, Inc. has a consensus price target of $288.70, signalling upside risk potential of 3.39%. On the other hand DexCom, Inc. has an analysts' consensus of $85.19 which suggests that it could grow by 16.64%. Given that DexCom, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe DexCom, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.047%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 41.88x while DexCom, Inc.'s PE ratio is 40.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 22.32x versus 6.59x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 10.24%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Krystal Biotech, Inc. has a consensus price target of $288.70, signalling upside risk potential of 3.39%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Krystal Biotech, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Amicus Therapeutics, Inc..

Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 41.88x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 22.32x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 21.74%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Krystal Biotech, Inc. has a consensus price target of $288.70, signalling upside risk potential of 3.39%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $842.42 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Krystal Biotech, Inc.'s net income of $79.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 41.88x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 22.32x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.